Lorlatinib

Lorlatinib (Lorbrena) is a prescription medication used to treat a certain type of non-small cell lung cancer. It is a type of targeted therapy, which means it works by targeting specific molecules involved in the growth and spread of cancer cells. Lorlatinib is used in people with a certain type of non-small cell lung cancer that has a specific genetic alteration (ALK, ROS1 or MET). It is usually taken by mouth in the form of a tablet once a day. Common side effects may include nausea, diarrhea, fatigue, and increased levels of liver enzymes.

Lorlatinib, sold under the brand name Lorbrena® in the US and Canada, is a medication used to treat a specific type of lung cancer [4]. Here's a breakdown of its key points:

• Type of drug: Lorlatinib is an ALK inhibitor, a type of targeted cancer therapy [2].
• Conditions it treats: Lorlatinib is FDA-approved for adults with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) that has spread to other parts of the body (metastatic) [4]. ALK is a protein that can be involved in the development of some cancers [2].
• How it works: Lorlatinib works by blocking the action of the ALK protein. This helps to slow or stop the growth of cancer cells [5].